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Abstract
Background
Practical methods of monitoring innate immune mucosal responsiveness are lacking. Lipo-
polysaccharide (LPS) is a component of the cell wall of Gram negative bacteria and a potent
activator of Toll-like receptor (TLR)-4. To measure LPS responsiveness of the nasal
mucosa, we administered LPS as a nasal spray and quantified chemokine and cytokine lev-
els in mucosal lining fluid (MLF).
Methods
We performed a 5-way cross-over, single blind, placebo-controlled study in 15 healthy non-
atopic subjects (n = 14 per protocol). Doses of ultrapure LPS (1, 10, 30 or 100μg/100μl) or
placebo were administered by a single nasal spray to each nostril. Using the recently devel-
oped method of nasosorption with synthetic adsorptive matrices (SAM), a series of samples
were taken. A panel of seven cytokines/chemokines were measured by multiplex immuno-
assay in MLF. mRNA for intercellular cell adhesion molecule-1 (ICAM-1) was quantified
from nasal epithelial curettage samples taken before and after challenge.
Results
Topical nasal LPS was well tolerated, causing no symptoms and no visible changes to the
nasal mucosa. LPS induced dose-related increases in MLF levels of IL-1β, IL-6, CXCL8 (IL-
8) and CCL3 (MIP-1α) (AUC at 0.5 to 10h, compared to placebo, p<0.05 at 30 and 100μg
LPS). At 100μg LPS, IL-10, IFN-α and TNF-α were also increased (p<0.05). Dose-related
changes in mucosal ICAM-1 mRNA were also seen after challenge, and neutrophils
appeared to peak in MLF at 8h. However, 2 subjects with high baseline cytokine levels
showed prominent cytokine and chemokine responses to relatively low LPS doses (10μg
and 30μg LPS).
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Conclusions
Topical nasal LPS causes dose-dependent increases in cytokines, chemokines, mRNA
and cells. However, responsiveness can show unpredictable variations, possibly because
baseline innate tone is affected by environmental factors. We believe that this new tech-
nique will have wide application in the study of the innate immune responses of the respira-
tory mucosa.
Key Messages
Ultrapure LPS was used as innate immune stimulus in a human nasal challenge model,
with serial sampling of nasal mucosal lining fluid (MLF) by nasosorption using a synthetic
absorptive matrix (SAM), and nasal curettage of mucosal cells. A dose response could be
demonstrated in terms of levels of IL-1β, IL-6, CXCL8 and CCL3 in MLF, as well as ICAM-1
mRNA in nasal curettage specimens, and levels of neutrophils in nasal lavage. Depending
on higher baseline levels of inflammation, there were occasional magnified innate inflamma-
tory responses to LPS.
Trial Registration
Clinical Trials.gov NCT02284074
Introduction
A range of inhaled and nasal challenges have been fundamental to our understanding of the
pathophysiology of allergy and asthma [1] [2]. Challenge tests give a controlled stimulus after
which serial measurements can be made, and the time course of responses can be assessed.
Experimental challenge studies with components of microbes (including pathogen associated
molecular patterns, PAMPs) and live viruses [3] give researchers the opportunity to study
mucosal host-microbial interactions in terms of the specific and innate immune systems [4,5].
The respiratory mucosa of the nose has an intricate sentinel role interacting with bacteria,
viruses and aeroallergens [6]. This is a complex and dynamic interaction that is mediated at a
molecular level by PAMPs interacting with host pattern recognition receptors (PRRs) [7,8].
Lipopolysaccharide (LPS) is contained in the wall of Gram negative bacteria and in a range of
microbes, and is a powerful PAMP with potent immunostimulatory properties through inter-
actions with Toll-like receptor (TLR)4. LPS represents the prototypic PAMP involved in cer-
tain bacterial infections [7], atopy [9], and in acute lung injury [10]. Interestingly, TLR4 is
involved in some viral infections [11]. House dust mite allergen has been shown to mimic an
LPS-binding component of the TLR4 signalling complex and causes activation of airway struc-
tural cells [12,13]. Environmental exposure to LPS in childhood may facilitate development of
tolerance to allergens [14], and this is one of a range of environmental microbial influences for
the development of allergy and asthma [15].
LPS has been employed extensively as a challenge agent by David Peden and coworkers:
with systemic administration by intravenous infusion [16], by inhalation from a nebulizer [17],
by segmental bronchial challenge [18] and by nasal challenge [19–22]. In particular, the group
of Lars-Olaf Cardell have carried out a series of studies with nasal LPS challenge: measuring
CCL3 (MIP1α) in nasal lavage [23], evaluating a CXCR2 antagonist [24], demonstrating that
Nasal LPS Challenge
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allergen primes LPS responses [25], and showing that LPS challenge has augmented nasal cyto-
kine release in allergic rhinitis [26].
Recently, synthetic absorptive matrices (SAM) have been used to sample mucosal lining
fluid (MLF) in the nose, followed by measurement of mediators. Nasosorption has been
employed in neonates [27], children with rhinitis [28] and in relation to nasal allergen chal-
lenge (NAC) [29]. The method of nasosorption has advantages in being non-invasive and
being able to sample neat MLF, which is eluted in a known volume of buffer [30]. Because
there is less dilution, nasosorption allows detection of higher levels of chemokines and cyto-
kines than after nasal lavage. An additional non-invasive sampling method employs nasal epi-
thelial curettage that has been employed to assess gene expression after nasal allergen challenge
[31] and experimental rhinovirus infection [32].
In this study we carry out topical nasal ultra-pure LPS challenge in healthy non-atopic vol-
unteers, and investigate the inflammatory response following a series of different doses of LPS.
We employed serial nasosorption sampling and measured levels of soluble chemokines and
cytokines using a multiplex immunoassay system. In addition, nasal epithelial curettage sam-
ples were taken for analysis of mRNA (transcriptomics) for intercellular cell adhesion mole-
cule-1 (ICAM-1) that is elevated in the nasal mucosa in allergic rhinitis [33].
Methods
Ethics and Consent
This study was approved by the South West London Research Ethics Committee. Since this
study was a topical challenge study for research purposes, and not for therapeutic benefit, the
study did not require authorization from the UKMedicines and Healthcare Products Regula-
tory Agency (MHRA). The study was carried out on the Imperial Clinical Respiratory Research
Unit (ICRRU) of St Mary’s Hospital in accordance with the Declaration of Helsinki and Good
Clinical Practice (GCP) guidelines.
Study Design
All healthy volunteers were recruited through newspaper advertising (Fig 1). The dose
response to LPS was assessed by a 5-way crossover, randomized, single-blind, placebo-con-
trolled study design (Fig 2). The dose randomization for the 5 arms (placebo, 1, 10, 30, 100μg
LPS/nostril) was performed by an independent statistician, employing a balanced Latin square
design to generate the order of challenges for each subject. The subjects were “blinded” to the
dosage being employed. Subjects were assigned to a sequence in accordance with a randomisa-
tion schedule generated prior to the start of the study. The randomisation was balanced over
the 5 nasal challenge sequences and was generated using RandAll, the GSK web-server based
clinical trials randomisation system.
Inclusion Criteria at Screening
Subjects were aged 18 to 60 years. They were current non-smokers for at least 6 months with a
smoking history of<5 pack years. These individuals had no history of atopy, rhinitis, asthma,
or other respiratory disease. Individuals with a history of malignancy or systemic disease were
excluded, and use of any inhaled or oral anti-inflammatory medication was not permitted.
LPS Administration
LPS solutions at concentrations of 10, 100, 300 and 1000μg/ml were prepared using ultra-pure
LPS from Escherichia coli 0111:B4 (Invivogen, San Diego, CA).This is a high quality source of
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LPS, that is specific for TLR4 and does not contain bacterial lipoprotein contaminants that acti-
vate TLR2 (manufacturer’s specification). LPS potency was confirmed within our laboratory
using the E-Toxate (Limulus Amoebocyte Lysate) kit (Sigma-Aldrich, Gillingham, UK). A
standard curve and dilutions of the test LPS were prepared and mixed with the lysate. The
ultra-pure LPS used in the clinical study contained 166–333 EU/μg, with the unit activity at the
higher end of the manufacturer’s specification on the Limulus assay.
Fig 1. Consort Flow Chart.
doi:10.1371/journal.pone.0135363.g001
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LPS and placebo were administered from a Pfeiffer Bidose nasal delivery device (Thermo-
fisher, Epsom, UK) by a physician. A volume of 100μl was administered as a spray to each nos-
tril, with a total dose per nostril of 1, 10, 30 or 100μg of LPS. Weights were recorded before and
after each actuation from the Pfeiffer Bidose, to check that a 100μg weight of fluid had been
delivered per nostril. A washout time of 12–28 days was employed between challenges.
Symptom Scores
Modified total nasal symptom scores (TNSS) were recorded at the initial screening visit and
before and at frequent intervals after nasal LPS challenge (-15 minutes, 30 minutes, then hourly
from 1 to 10 hours and then at 24h post-LPS). Nasal congestion, rhinorrhea, sneezing, and
nasal itch were scored from 0 to 3 (0: no, 1: mild, 2: moderate, 3: severe symptoms). The scores
were then summed to give a final TNSS out of a maximum of 12.
We also measured safety parameters (temperature, heart rate, blood pressure and oxygen
saturations), performed regular nasal mucosal inspections, and assessed peak nasal inspiratory
flow (PNIF)
Nasal Lavage
Amodified nasal pool technique was adapted from the method of Greiff et al [34]. The subjects
were seated in a forward-flexed neck position (60 degrees from the upright position) to prevent
fluid from reaching the nasopharynx. To ensure adequate washing, the lavage fluid (5ml of
0.9% normal saline) was passed via a 10ml syringe slowly into the nasal cavity via an olive con-
sisting of an oval, hollow, stainless steel device that was used to obstruct the nostril. The fluid
was withdrawn into the syringe and gently flushed back into the nasal cavity 20 times over 1
minute.
Nasal lavage samples were initially centrifuged (4°C, 10 min at 400g), and the cell pellet
resuspended in 0.01% dithiothreitol in phosphate buffered saline (PBS). The samples were
gently agitated on a rolling mixer for 10 minutes and centrifuged; the supernatant was
Fig 2. Nasal lipopolysaccharide challenge study design and procedures. 14 subjects completed the entire protocol (per protocol), while 1 subject only
received nasal challenges at placebo and LPS. TNSS–total nasal symptom score. AE–adverse events
doi:10.1371/journal.pone.0135363.g002
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discarded; the pellet was resuspended in PBS at 1 to 2 million cells/mL, and cytospin slides
were prepared. Differential leukocyte counts were determined by assessment of 400 leukocytes
on the stained cytospin.
Nasosorption
Nasosorption was performed with strips of synthetic absorptive matrix (SAM; Fibrous Polyes-
ter; Hunt Developments, Midhurst, West Sussex, UK). The SAM was inserted under direct
vision into the nasal cavity, the length being applied laterally against the anterior inferior turbi-
nate. Nose clips were used to ensure good contact with the mucosal surface. Pre-chilled assay
buffer (PBS, bovine serum albumin (BSA) 1%; Tween-20 0.05%, sodium azide 0.08% (Milliplex
Assay Buffer, cat no. L-AB, Merck Millipore, Billerica, Mass., USA), was dispensed in 500μL
aliquots into filter cups within Eppendorf tubes (Costar spin-X, cellulose acetate). After
removal of the SAM strips from the nose, they were placed in the assay buffer, and spin filtra-
tion was performed (4°C for 5 min at 16,000 g). The eluate was collected and stored as aliquots
at -80°C, prior to assay of chemokines and cytokines by a multiplex immunoassay (Mesoscale
Diagnostics, MSD, Gaithersburg, Md, USA).
Cytokine levels in Nasosorption Samples
Two custom 7-spot MSD plates (MSD) were used for measuring the concentrations of CCL3
(MIP-1α), IL-1β, IL-6, CXCL8 (IL-8), TNF-α, IFN-α, IL-10 (Plate 1) and IFN-γ, GM-CSF,
CCL2 (MCP-1), CXCL10 (IP-10), IL-12p70, IL-17 (Plate 2). The plates provided are pre-coated
with antibody for the specific analytes. Diluent 2 (MSD) (25μl) was added to each well and the
plate was incubated for 30 min while being vigorously shaken. All incubations in the MSD
immunoassay were done on an orbital shaker at 1000 rpm at room temperature. 25μL of the
sample or calibrator was added to each well. A standard curve of calibrators (10000, 2500,
625, 156.3, 39.1, 9.8 and 2.4pg/mL) was run in duplicate. Controls of known concentrations
(625pg/mL and 9.8pg/mL) were done in quadruplicate. Three replicates of each sample were
added. After an incubation of 2 hours on a shaker with the sample/calibrator the plates were
washed three times with PBS + 0.05% Tween and then 25μL of 1X Detection Antibody Solution
was added to each well. After incubation for 2 hours with vigorous shaking the plate was
washed 3 times with PBS + 0.05% Tween. 150μL of 2X Read Buffer was added to each well and
the plate was read immediately using a MSD Sector Imager 6000. The raw data was analysed
using MSD Discovery Workbench 3.0 software. The concentration of each cytokine was calcu-
lated from the standard curve of the Calibrators.
Nasal Epithelial Curettage
A single nasal curettage was performed at baseline and again at 3, 6, and 24hrs to obtain epithe-
lial cells for mRNA gene expression studies using a plastic nasal curette (Rhinoprobe, Arlington
Scientific). All nasal scrapes were performed after the collection of nasosorption and nasal
lavage samples. Nasal scrapes were taken from the posterior aspect of the inferior turbinate,
without local anaesthesia, collecting a single 5mmmucosal sample. Nasal scrapes were placed
in labelled sterile tubes containing TRIzol reagent (500μl) and stored at -80°C.
Analysis of ICAM-1 mRNA expression from nasal Rhinoprobe samples
by RT-qPCR
Nasal scrapes samples were placed in TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) and
stored at -80°C until the total RNA was purified. Total RNA was extracted using RNeasy Mini-
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kit (Cat. No. 74104, Qiagen Gmbh, Hilden, Germany) and treated with RNase-free DNase (Cat.
No. 79254, Qiagen) according to the instructions of the manufacturer. RNA concentrations were
determined with a NanoDrop 8000 Spectrophotometer (Thermo Scientific, Wilmington, DE,
USA). cDNA was synthesized using the Applied Biosystems High Capacity cDNA Reverse Tran-
scriptase Kit (catalogue number 4368813) with 3ng of RNA in a final reaction volume of 20μl. The
reaction was incubated at 25°C for 10 minutes, followed by 2 hours at 37°C. qPCR was performed
using the Taqman universal PCRmaster mix (Applied Biosystems Catalogue number 4318157)
on an 7900HT Fast Real Time PCR System. Six replicates were run per sample. Sequences of
Taqman primer/probes were as follows: Human ICAM-1 forward primer 5’-GCTCTGCAACCC
TGGAGGT-3’; reverse primer 5’-GGCCATACAGGACACGAAGC-3’; Probe CCAGCTTATAC
ACAAGAACCAGACCCGG. All data was normalised using Human GAPDH as a housekeeper
gene. GAPDH forward primer 5’-CAAGGTCATCCATGACAACTTTG-3’; Reverse primer
5’-GGGCCATCCACAGTCTTCT-3’; Probe ACCACAGTCCATGCCATCACTGCCA.
Statistical analysis
Biomarker data was available for 15 subjects although subject number 3102 withdrew after 2
periods. For all biomarkers, the lower limit of quantitation (LLOQ) was taken as 9.8pg/ml and
a value of LLOQ/2 (= 4.9pg/ml) was used for all values less than the LLOQ. The median was
taken of the 3 adjusted readings and used in the analysis. The area under curve (AUC) from
0-10h of the observed data were calculated for each dose of LPS, and responses after LPS chal-
lenge described as changes relative to placebo AUC 0-10h. The distribution of the AUC data
was tested using a Shapiro-Wilks test and significant deviations from normal data distribution
were seen. Therefore non-parametric statistics (Wilcoxon signed rank test) were applied
throughout.
Statistical analysis of ICAM-1 mRNA data was performed in SAS v9.2 using a mixed model
analysis of variance. All subjects received each of the treatments at a separate visit and within
each visit a response across time was obtained. Due to the complex design of the study ‘time’
was included in the model as a repeated measures and ‘subject/ visit’ was included as a random
effect to allow the appropriate error structure to be used for assessing LPS effects at each time
point. The response used was logged gene abundance and log GAPDH (glyceraldehyde-
3-phosphate dehydrogenase) was included as a covariate so that the resulting estimates of the
mean fold changes from placebo were normalised.
Results
Baseline Demographics
Subjects were recruited through newspaper adverts and all visits took place between November
and April (Fig 2). Following initial entry of 17 subjects, a total of 14 subjects completed all
study visits and sampling procedures (per protocol group). A single individual received 2 doses
(placebo and LPS at 100μg) and was included in the analysis, so that 15 subjects were studied.
Subjects ranged in age from 21 to 57 years (mean 38 years), and there were 10 males and 5
females.
One individual withdrew from the study following development of an infective pyelonephri-
tis 10 days after a low dose of LPS (1μg), this being the first nasal challenge, and the event was
considered to be “not clinically related to LPS administration”. A second individual was with-
drawn from the study after 2 of the 5 planned nasal challenges, as they had withheld medical
information that excluded their participation. These 2 subjects were excluded from the
analysis.
Nasal LPS Challenge
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Clinical Symptom Scores
None of the participants experienced any significant clinical symptoms during the course of
their study participation. Following nasal LPS administration there were no visible signs of
inflammation on direct examination of the nasal mucosa by a physician.
Levels of Cytokines and Chemokines in Nasal MLF
Following nasal LPS challenge there was a dose response for IL-1β, IL-6, CXCL8, CCL3 and IL-
10 levels in nasal SAM eluate. Median levels of these cytokines and chemokines over time are
shown in Fig 3. Although there was an increase in the response to nasal LPS at doses up to
30μg, the response at 30 and 100μg was approximately equivalent.
The Area Under the Curve (AUC) for individual biomarkers measured at 0.5 to 10h was
compared with placebo. Following LPS there were significant increases in AUC for IL-1β, IL-6,
CXCL8, and CCL3 (Table 1). IL-10, IFN-α and TNF-α were increased significantly at 100μg
alone. There were particularly marked IL-1β and IL-6 responses and AUC data is shown in
response to nasal LPS dose as medians with quartiles, and individual AUC responses in Fig 4.
Idiosyncratic Responses (2)
Examining the levels of cytokines and chemokines in nasal SAM eluates from individual sub-
jects, it was noted that 2 subjects had unexpectedly large responses to LPS on a single occasion
during dose-escalation. This is illustrated in Fig 4 (lower portion) that shows levels of cytokines
and chemokines as AUC from 0.5h to 10.0h. These markedly elevated responses occurred in
Fig 3. Median levels of chemokines and cytokines (pg/ml) in nasal mucosal lining fluid (MLF) are shown after nasal spray challenge with 4 different
doses of LPS and a placebo (see key below). Lower limits of detection (LLOD) for cytokines and chemokines were as follows: IL-1β (5.0pg/ml), IL-6 (5.0pg/
ml), CXCL8/IL-8 (10.0pg/ml), CCL3/MIP-1α (5.0pg/ml), CCL2/MCP-1 (25.0pg/ml), IL-10 (5.0pg/ml). Time -0.5h refers to nasosorption performed 30 min prior
to topical nasal challenge, and this varies considerably between individuals due to variations in individual’s microbial flora and mucosal immune responses.
Nasal lavage was performed after nasosorption at -0.5h, but prior to nasal challenge, in order to partially wash the nose free of baseline inflammatory
microbes and mediators, but causes detectable levels of inflammatory mediators at 0.5h to decrease markedly from -0.5h. There is a tendency for
nasosorption levels of mediators to gradually increase from 0.5h to 10h in the placebo arm, but levels of inflammatory cytokines and chemokines after LPS
are generally higher.
doi:10.1371/journal.pone.0135363.g003
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subject 2009 following 10μg LPS, and in subject 2101 following 30μg LPS. With regards to the
order of challenges, subject 2009 received 10μg as their second dose (100μg, 10μg, 1μg, placebo,
30μg), while subject 3101 received 30μg LPS as their first dose (30μg, 100μg, 1μg, placebo,
10μg). This suggests that sensitisation to LPS is not the explanation for these large idiosyncratic
responses.
Following the 2 idiosyncratic responses to nasal LPS, the raw data for nasal SAM eluate lev-
els of cytokines and chemokines is presented in Fig 5. In subject 2009 the response was mainly
in terms of IL-6 and IL-1β, while in subject 3101 CCL2 (MCP-1) was also elevated. It was note-
worthy that on the occasion of both these idiosyncratic responses, there were high baseline lev-
els of nasal MLF IL-1β and IL-6.
Levels of Nasal Lavage Neutrophils
There was an increase in the number of neutrophils in nasal lavage from baseline at 4h with
doses of LPS at 1, 30 and 100μg (Fig 6). However, changes did not reach significance, and there
was not dose-related. This is in keeping with our experience that nasal lavage is a somewhat
unreliable sampling method, and that subsequent cell counts can be variable.
ICAM-I mRNA
ICAMmRNA expression was measured in nasal curettage samples by quantitative PCR
(qPCR). Samples were taken 30 minutes before LPS challenge and at 3, 6 and 24 hours post
challenge. A dose dependent increase in ICAM-1 mRNA expression was observed following
LPS treatment (Fig 7). The maximal increase in ICAM-1 mRNA over placebo was observed at
6 hours post LPS challenge: 1μg LPS (p<0.05), 10μg LPS (p<0.01), 30μg LPS (p<0.01) and
100μg LPS (p<0.0001). A significant increase over placebo was also observed at 3 hours for the
30μg and 100μg groups (both at p<0.05). ICAM-1 mRNA expression levels returned to base-
line at 24h post LPS treatment.
Discussion
This 5-way crossover study documents the nasal mucosal immune response to LPS challenge
by performing serial non-invasive sampling (nasosorption and nasal epithelial curettage) and
then measuring levels of cytokines and chemokines together with mRNA for ICAM-1. Original
features of this report include the use of ultrapure LPS, serial nasal sampling by the novel
Table 1. Statistical analysis of levels of cytokines and chemokines in nasal mucosal lining fluid1.
Cytokine or chemokine Nasal challenge LPS, 1μg Nasal challenge LPS, 10μg Nasal challenge LPS, 30μg Nasal challenge LPS, 100μg
IL-1β ns <0.05 <0.05 <0.01
IL-6 ns ns <0.05 <0.05
CXCL8 (IL-8) ns ns <0.05 <0.01
CCL3 (MIP-1α) <0.05 ns <0.05 <0.001
CCL2 (MCP-1) ns <0.05 ns ns
IL-10 ns ns ns <0.05
IFN-α ns ns ns <0.05
TNF-α ns ns ns <0.05
1Footnote: Area Under the Curve (AUC) for individual cytokines or chemokines measured at 0.5 to 10h was compared with placebo. The non-parametric
Wilcoxon signed rank test was used for statistical analysis. Probability (p) values are presented, ns = non signiﬁcant. The levels of the following cytokines
and chemokines were not signiﬁcantly altered by LPS: IFN-γ, GM-CSF, CXCL10 (IP-10), IL-12p70, IL-17.
doi:10.1371/journal.pone.0135363.t001
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Fig 4. Levels of interleukins (IL) in nasosorption eluates presented as area under the curve (AUC) for times 0.5-10h in relation to topical nasal
challenge (n = 14 or 15). AUC is derived from from 0.5 since the baseline sample at -0.5h is pre-nasal lavage and is highly variable due to difference in
individuals in terms of nasal microbes and inflammatory mediators. A) IL-1β as medians with quartiles; B) IL-6 as medians with quartiles; C) IL-1β AUC data
for individual subjects; D) IL- AUC data for individual subjects. Note the idiosyncratic large responses of subject 2009 after nasal challenge with 10μg LPS,
and subject 3101 after nasal challenge with 30μg LPS, these responses being too large to be presented on the y axis.
doi:10.1371/journal.pone.0135363.g004
Nasal LPS Challenge
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Fig 5. Idiosyncratic large nasal responses to lipopolysaccharide (LPS) on 2 occasions. Raw data for levels of chemokines and cytokines (pg/ml) in
nasal mucosal lining fluid (MLF). Data is presented for individual subjects: A. Subject 2009 after nasal challenge with 10μg LPS. B. Subject 3101 after nasal
challenge with 30μg LPS. Note that baseline levels of cytokines and chemokines at -0.5h are markedly raised, and come down to only a small extent after
nasal lavage at 0.5h. It is suggested that these individuals may have had a non-symptomatic alteration in their nasal microbial flora prior to LPS challenge on
these opccasions: possibly the individuals had a subclinical viral infection or bacterial colonisation.
doi:10.1371/journal.pone.0135363.g005
Fig 6. Nasal lavage leukocyte counts (medians expressed as cells/ml) following nasal LPS challenge.Cells were counted in a modified Neubauer
chamber, and a leukocyte differential performed on a stained cytospin observed under a light microscope.
doi:10.1371/journal.pone.0135363.g006
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method of nasosorption, employing LPS at a range of 4 doses, measuring a range of cytokines
and chemokines using a multiplex immunoassay, and assessment of mRNA in epithelial curet-
tage specimens. We were able to observe a dose response to LPS up to 30μg in terms of signifi-
cantly increased levels of IL-1β, IL-6, CXCL8 and CCL3, which suggests that the dose of 50μg
per nostril employed by Cardell and co-workers is optimal in non-atopic subjects [23] [26,35].
Other nasal LPS challenge studies have demonstrated increases in IL-6 [20,36], CXCL8 [21,35]
and CCL3 [23].
In the situation of a nasal topical challenge and wishing to take a series of repeated samples
from the nasal mucosa, nasosorption of mucosal lining fluid has advantages over nasal lavage.
In a study if repeated sampling in healthy volunteers, it was found that nasal lavage levels of a
range of mediators were approximately 10-times lower than those from nasosorption eluates
[37]. This was confirmed in a study of levels of IL-4, IL-5 and IL-13 after nasal allergen chal-
lenge (NAC), where levels of these interleukins were higher in nasosorption eluates, and fre-
quently undetectable in nasal lavages [38]. In a recent study it was found that repeating nasal
Fig 7. ICAM-1mRNA abundance within nasal curettage samples after nasal LPS challenge, Data is shown as means with 95% confidence
intervals. Relative abundance of expression with Reverse Transcriptase quantitative Polymerase Chain Reaction (RT-qPCR) using normalized data and
(glyceraldehyde-3-phosphate dehydrogenase) (GAPDH) as a housekeeper gene (see Methods).
doi:10.1371/journal.pone.0135363.g007
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lavage within 0.5 to 4h caused markedly decreased levels of mediators, and they concluded that
nasal lavage can only be performed once daily to get comparable results [39].
Using a modified nasal lavage collection method, a recent nasal LPS challenge study failed
to show significant cytokine responses in allergic rhinitis patients, but amplified responses
occurred when nasal allergen challenge preceded nasal LPS challenge [26]. The reason our
study was able to document a dose response was probably because we utilized nasosorption to
obtain nasal MLF, while other studies have generally measured more dilute nasal secretions
present in nasal lavage.
An interesting finding in the study was that in 2 subjects there were large idiosyncratic
responses to submaximal doses of LPS. Whereas the median response following higher doses
of LPS may be up to 5 times greater than that after placebo, the idiosyncratic reactions involved
IL-6 and IL-1β responses of greater than 1000 times those of placebo. Despite these large
inflammatory reactions, subjects reported no symptoms, and there were no visible signs of
nasal inflammation. When we assessed the sequence of LPS administrations, there was no evi-
dence of a sensitization or tolerization process occurring with earlier doses. The phenomenon
of tolerance to endotoxin has been demonstrated when low dose endotoxin is administered
nasally up to 3 times on consecutive days [19,22],
The idiosyncratic exaggerated reactions occurred in one subject after 10μg LPS and in
another subject at 30μg LPS. The upper respiratory tract is now recognised to contain a vast
array of commensal and pathogenic bacteria included within the nasal microbiome, and these
may interact with aeroallergens [40] [9]. In asymptomatic healthy individuals there is fre-
quently carriage of the potential pathogens Staphylococcus aureus and Streptococcus pneumo-
niae. There is then extensive crosstalk among PAMPs, TLRs and other innate PRRs in the
mucosa [7]. Interestingly the mucosal relationship with bacteria and viruses is altered in the
asthmatic or allergic airway. In particular, TLR4 signalling in stromal cells has been shown in
mice to be critical for initiation of allergic Th2 responses [41].
We are not currently able to explain these idiosyncratic responses, but each case there were
high levels of IL-1β and IL-6 in nasal mucosal lining fluid before challenge. This leads us to
speculate that the idiosyncratic reactions relate to pre-activation by variations in nasal exposure
to aeroallergens, viruses or bacteria.
In addition LPS caused a dose response in terms of induction of gene expression for ICAM-
1, that is upregulated following inflammation, and acts as an epithelial receptor for human rhi-
noviruses (HRV). ICAM-1 is upregulated in the nasal mucosa of allergic rhinitis patients [33],
and HRV causes activation of epithelial cells through this receptor. Measurement of soluble-
ICAM-1 in nasal MLF would confirm whether the increased ICAM-1 gene expression relates
to increased production of protein.
In conclusion, this study demonstrates a dose response to nasal LPS challenge in terms of
levels of cytokines and chemokines measured in serial nasal MLF samples, and also with raised
levels of ICAM-1 mRNA being found in serial nasal epithelial curettage samples. However, we
also highlight the occasional phenomenon of an idiosyncratic large response to LPS, which is
not dose-related, and that occurred in 2 subjects on single occasions.
In future studies this method, we intent do examine mucosal immune responses to a series
of different challenge agents ranging from allergens, diverse microbial components and live
viruses. We will also study the longitudinal responses to LPS and other agents over time and to
document the influences of one nasal challenge agent on another (as has been done for nasal
allergen challenge followed by LPS challenge [26]). Finally, in assessing the response to these
nasal challenges in patients with allergic rhinitis and asthma, it may be possible to characterize
mucosal immunology in individual patients as a basis for rational therapy.
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